Is IGM Biosciences Stock a Good Investment?
IGM Biosciences Investment Advice | IGMS |
- Examine IGM Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research IGM Biosciences' leadership team and their track record. Good management can help IGM Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact IGM Biosciences' business and its evolving consumer preferences.
- Compare IGM Biosciences' performance and market position to its competitors. Analyze how IGM Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if IGM Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about IGM Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in IGM Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if IGM Biosciences is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine IGM Biosciences Stock
Researching IGM Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 38.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.27. IGM Biosciences had not issued any dividends in recent years.
To determine if IGM Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding IGM Biosciences' research are outlined below:
| IGM Biosciences generated a negative expected return over the last 90 days | |
| IGM Biosciences may become a speculative penny stock | |
| IGM Biosciences has high historical volatility and very poor performance | |
| IGM Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.68 M. Net Loss for the year was (195.79 M) with loss before overhead, payroll, taxes, and interest of (129.42 M). | |
| IGM Biosciences currently holds about 469.14 M in cash with (153 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Concentra Group to Acquire IGM Biosciences - MSN |
IGM Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in IGM Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to IGM Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact IGM Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises IGM Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-03-26 | 2019-12-31 | -0.43 | -0.49 | -0.06 | 13 | ||
2025-03-05 | 2024-12-31 | -0.7106 | -0.61 | 0.1006 | 14 | ||
2023-11-13 | 2023-09-30 | -1.21 | -1.04 | 0.17 | 14 | ||
2024-11-11 | 2024-09-30 | -0.8 | -1.01 | -0.21 | 26 | ||
2022-08-08 | 2022-06-30 | -0.94 | -1.33 | -0.39 | 41 | ||
2025-05-06 | 2025-03-31 | -0.45 | -0.86 | -0.41 | 91 | ||
2024-08-14 | 2024-06-30 | -0.04 | -0.79 | -0.75 | 1875 | ||
2019-11-07 | 2019-09-30 | -0.82 | -2.41 | -1.59 | 193 |
Know IGM Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as IGM Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IGM Biosciences backward and forwards among themselves. IGM Biosciences' institutional investor refers to the entity that pools money to purchase IGM Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2025-03-31 | 187 K | Two Sigma Investments Llc | 2025-03-31 | 139.8 K | Charles Schwab Investment Management Inc | 2025-03-31 | 125.6 K | Verition Fund Managegment, Llc | 2025-03-31 | 119.1 K | Bruce & Co Inc | 2025-03-31 | 100 K | Eagle Bay Advisors Llc | 2025-06-30 | 99.6 K | Two Sigma Advisers, Llc | 2025-03-31 | 90.5 K | Acadian Asset Management Llc | 2025-03-31 | 85.8 K | Woodline Partners Lp | 2025-03-31 | 69.6 K | Baker Bros Advisors Lp | 2025-03-31 | 4.1 M | Siren, L.l.c. | 2025-03-31 | 3.3 M |
IGM Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 76.44 M.Market Cap |
|
IGM Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.74) | (0.77) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.74) | (0.77) | |
| Return On Equity | (4.06) | (3.86) |
Determining IGM Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if IGM Biosciences is a good buy. For example, gross profit margin measures IGM Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of IGM Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in IGM Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IGM Biosciences. Check IGM Biosciences' Beneish M Score to see the likelihood of IGM Biosciences' management manipulating its earnings.
Evaluate IGM Biosciences' management efficiency
IGM Biosciences has return on total asset (ROA) of (0.3678) % which means that it has lost $0.3678 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4559) %, meaning that it created substantial loss on money invested by shareholders. IGM Biosciences' management efficiency ratios could be used to measure how well IGM Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.77 in 2025. Return On Capital Employed is likely to drop to -0.96 in 2025. At this time, IGM Biosciences' Total Assets are comparatively stable compared to the past year. Other Assets is likely to gain to about 2.4 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 47.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.80 | 0.84 | |
| Tangible Book Value Per Share | 0.80 | 0.84 | |
| Enterprise Value Over EBITDA | (1.95) | (2.04) | |
| Price Book Value Ratio | 7.68 | 8.06 | |
| Enterprise Value Multiple | (1.95) | (2.04) | |
| Price Fair Value | 7.68 | 8.06 | |
| Enterprise Value | 388.4 M | 508.7 M |
IGM Biosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.511 |
Basic technical analysis of IGM Stock
As of the 23rd of July, IGM Biosciences retains the market risk adjusted performance of 0.1564, and Risk Adjusted Performance of 0.0474. IGM Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out IGM Biosciences coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if IGM Biosciences is priced fairly, providing market reflects its last-minute price of 1.27 per share. Given that IGM Biosciences is a hitting penny stock territory we urge to closely look at its total risk alpha.IGM Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IGM Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on IGM Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IGM Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
IGM Biosciences' Outstanding Corporate Bonds
IGM Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. IGM Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most IGM bonds can be classified according to their maturity, which is the date when IGM Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand IGM Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing IGM Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0474 | |||
| Market Risk Adjusted Performance | 0.1564 | |||
| Mean Deviation | 2.96 | |||
| Semi Deviation | 3.57 | |||
| Downside Deviation | 4.14 | |||
| Coefficient Of Variation | 2287.0 | |||
| Standard Deviation | 4.33 | |||
| Variance | 18.74 | |||
| Information Ratio | 0.0025 | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.63) | |||
| Sortino Ratio | 0.0026 | |||
| Treynor Ratio | 0.1464 | |||
| Maximum Drawdown | 25.54 | |||
| Value At Risk | (5.93) | |||
| Potential Upside | 6.45 | |||
| Downside Variance | 17.13 | |||
| Semi Variance | 12.77 | |||
| Expected Short fall | (3.67) | |||
| Skewness | 0.7269 | |||
| Kurtosis | 3.05 |
| Risk Adjusted Performance | 0.0474 | |||
| Market Risk Adjusted Performance | 0.1564 | |||
| Mean Deviation | 2.96 | |||
| Semi Deviation | 3.57 | |||
| Downside Deviation | 4.14 | |||
| Coefficient Of Variation | 2287.0 | |||
| Standard Deviation | 4.33 | |||
| Variance | 18.74 | |||
| Information Ratio | 0.0025 | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.63) | |||
| Sortino Ratio | 0.0026 | |||
| Treynor Ratio | 0.1464 | |||
| Maximum Drawdown | 25.54 | |||
| Value At Risk | (5.93) | |||
| Potential Upside | 6.45 | |||
| Downside Variance | 17.13 | |||
| Semi Variance | 12.77 | |||
| Expected Short fall | (3.67) | |||
| Skewness | 0.7269 | |||
| Kurtosis | 3.05 |
Consider IGM Biosciences' intraday indicators
IGM Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of IGM Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 1.27 | |||
| Day Typical Price | 1.27 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 58.94 |
IGM Stock media impact
There is far too much social signal, news, headlines, and media speculation about IGM Biosciences that are available to investors today. This information is accessible both publicly - through IGM Biosciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of IGM-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of IGM Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of IGM Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to IGM Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive IGM Biosciences alpha.
IGM Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards IGM Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
IGM Biosciences Historical Investor Sentiment
Investor biases related to IGM Biosciences' public news can be used to forecast risks associated with an investment in IGM. The trend in average sentiment can be used to explain how an investor holding IGM can time the market purely based on public headlines and social activities around IGM Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
IGM Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for IGM Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average IGM Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on IGM Biosciences.
IGM Biosciences Corporate Management
| TS Harigopal | Senior Operations | Profile | |
| Faraz Siddiqui | Senior Operations | Profile | |
| Angus Sinclair | Senior ImmunoOncology | Profile | |
| Elizabeth JD | Senior Property | Profile | |
| Elaine Sapinoso | Senior Quality | Profile | |
| Misbah CPA | Chief Officer | Profile | |
| Lisa Decker | Chief Officer | Profile |
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.